Kidney transplant outcomes in patients with complement dysregulation

doi:10.5500/wjt.120969

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

(8)

(9)

(0)

(5)

(75)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Transplant. Sep 18, 2026; 16(3): 120969
Published online Sep 18, 2026. doi: 10.5500/wjt.120969

Table 5 Characteristics of recurrence cohort (n = 7)

Case	Complement genetic abnormality	AFH ≥ 100	Genetic details	Pre-transplant treatment	Post-transplant treatment	Outcome
1	Present	Yes	CFHR1-CFHR3 homozygous deletion	-	5 PE + rituximab (500 × 2)	Functioning graft
2	Present	Yes	CFHR1-CFHR3 duplication	6 PE + rituximab 500 mg	Modified immunosuppression	Functioning graft
3	Present	No	CFH heterozygous + CFHR1/3 duplication	3 PE + rituximab 500 mg	4 PE	Functioning graft
4	Present	No	CFHR1-CFHR3 duplication	5 PE + rituximab 500 mg	3 PE + IVIG + bortezomib	Functioning graft
5	Present	No	CFHR1-CFHR3 duplication	-	PE	Graft loss (history of mucormycosis)
6	Present	No	CFHR1 heterozygous	-	4 PE + rituximab 200 mg	Functioning graft
7	Present	No	CFHR1 heterozygous	-	3 PE + eculizumab	Functioning graft

Numbers preceding plasma exchange indicate the number of plasma exchange sessions administered. Rituximab doses are expressed per administration. AFH: Anti-factor H antibody; CFH: Complement factor H; CFHR: Complement factor H-related protein; IVIG: Intravenous immunoglobulin; PE: Plasma exchange.

Full Size Table

Citation: Balwani M, Pasari A, Kashiv P, Ramteke V, Tolani P, Manuja N, Kurundwadkar M, Dubey S, Pawar T, Malde S, Gupta S, Sejpal K, Jeyachandran V, Kute VB. Kidney transplant outcomes in patients with complement dysregulation. World J Transplant 2026; 16(3): 120969
URL: https://www.wjgnet.com/2220-3230/full/v16/i3/120969.htm
DOI: https://dx.doi.org/10.5500/wjt.120969

Balwani M, Pasari A, Kashiv P, Ramteke V, Tolani P, Manuja N, Kurundwadkar M, Dubey S, Pawar T, Malde S, Gupta S, Sejpal K, Jeyachandran V, Kute VB. Kidney transplant outcomes in patients with complement dysregulation. World J Transplant 2026; 16(3): 120969 [DOI: 10.5500/wjt.120969]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.